relatlimab (BMS-986016) - BMS
Yervoy (ipilimumab) - BMS
Opdivo (nivolumab) - Ono Pharmaceutical, BMS
Keytruda (pembrolizumab) - Merck (MSD)
Libtayo (cemiplimab-rwlc) - Regeneron
Contemporary Multimodal Management of Cutaneous Malignancies: Surgery, Radiotherapy, Systemic Therapy, Molecular Targeting and Immunotherapy. (PubMed, Cancers (Basel)) - Sep 27, 2026 - "The major unresolved issues are optimal sequencing, response-adapted perioperative treatment, resistance, biomarker validation and treatment of transplant, frail and other under-represented populations." 
IO biomarker • Journal • Review • Tumor mutational burden • Basal Cell Carcinoma • Cutaneous Melanoma • Genetic Disorders • Melanoma • Merkel Cell Carcinoma • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Skin Cancer • Transplantation • NF1 • NRAS • PD-L1 • TMB
http://www.ncbi.nlm.nih.gov/pubmed/42794996
 
Andrzej Ciborek; Dariusz Kowalczyk; Hanna Krauss; Jolanta Jaworek; Pawel Antoni Kolodziejski
 
Sep 27, 2026
 
Prev Next